Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 02, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on November 30, 2005, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 897 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on December 1, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held in the GSK Trust in the same manner as other employees. The notification complies with Disclosure Rule 3.1.4R (1) (b).
Investor Verification Checklist
- Verify the total number of shares transferred (897) and the date of transfer (November 30, 2005).
- Confirm the identity of the trustee (Abacus (GSK) Trustees Limited) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Review the disclosure regarding the three directors with interests in the GSK Trust.
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.